What happened with AGEN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Agenus Inc. is a clinical-stage biotechnology company developing treatments that use the immune system to fight cancer. Its main focus is botensilimab, used alone or with balstilimab. It has temporarily paused some other research and development to concentrate resources on these programs.
Hospitals and physicians pay Agenus for botensilimab and balstilimab supplied through France’s compassionate-access framework and paid named-patient programs where permitted. These programs allow access before marketing approval; they do not authorize general commercial sale, and authorities may change or discontinue them.
Most reported revenue comes from royalties linked to GSK vaccines containing QS-21 STIMULON, a substance that enhances a vaccine’s immune response. However, Agenus sold those royalty rights to Healthcare Royalty Partners, which receives the payments directly. This revenue therefore does not bring cash into Agenus.
Agenus relies exclusively on Zydus to manufacture botensilimab and balstilimab for trials, access programs and potential commercialization. Zydus also holds development and commercialization rights in India and Sri Lanka, with royalties payable to Agenus if sales occur. Agenus’s business depends on further clinical development and regulatory approval of its lead treatments, partner performance and additional funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Agenus’s prospects hinge on BOT/BAL’s clinical and regulatory progress and exclusive manufacturing supply from Zydus, rather than the noncash GSK vaccine royalties that dominate reported revenue.
Adagene’s lead cancer-antibody candidate ADG126 competes with Agenus’s botensilimab at the same CTLA-4 target. Watch its combination trials with pembrolizumab in refractory colorectal cancer, where the two companies’ treatment programs overlap.
Xilio Therapeutics’ CTLA-4 cancer-antibody program competes with Agenus’s botensilimab, including combinations for refractory colorectal cancer. Its search for a partner for vilastobart and trials with atezolizumab are the developments to watch for this competing program.
Exelixis’s zanzalintinib-plus-atezolizumab regimen directly competes with Agenus’s BOT/BAL for refractory non-MSI-H/dMMR colorectal cancer patients. Although Exelixis earns most revenue from cabozantinib medicines, its December 2025 US approval application for zanzalintinib and the STELLAR-303 trial matter more for this rivalry.
Bristol Myers Squibb sells Yervoy, a CTLA-4 cancer therapy that competes with Agenus’s next-generation botensilimab. That rivalry remains separate from its AGEN1777 license, which ended on January 26, 2025, returning the rights to Agenus.
Merck competes with Agenus through Keytruda and newer immune-checkpoint cancer programs, but also funds development of Agenus-discovered MK-4830 under license, with potential milestone and sales-royalty payments to Agenus. Watch the remaining ovarian-cancer study with pembrolizumab and chemotherapy: Merck narrowed further MK-4830 development to that study in 2024.
AstraZeneca already sells cancer therapies targeting CTLA-4 and PD-L1—tremelimumab and durvalumab—that compete with Agenus’s BOT/BAL approach. Its clinical programs targeting CTLA-4, TIGIT and TIM-3 add further overlap with pathways pursued by Agenus and its partners.
Replimune develops cancer treatments using oncolytic viruses that Agenus identifies as competitors to botensilimab and its refractory colorectal cancer combinations. Watch its virus candidates combined with bevacizumab and atezolizumab; it had no approved products or product-sale revenue through the fiscal year ended March 31, 2026.
CytomX’s Varseta-M competes for colorectal cancer patients with Agenus’s therapies, using a masked antibody carrying a drug rather than immune-checkpoint blockade. Watch Varseta-M’s trial progress and supply: CytomX relies on sole-source contractors, and manufacturing failures could delay trials.
GSK’s sales of vaccines using Agenus’s licensed QS-21 ingredient drive most of Agenus’s reported revenue, but GSK pays the cash royalties to HCR, not Agenus. Watch sales of QS-21-containing vaccines including Shingrix and Arexvy: these generated about $108.6 million of noncash royalty revenue for Agenus in 2025.
Agenus holds a material equity investment in MiNK Therapeutics, so MiNK matters as an investment as well as a developer of donor-derived iNKT immune-cell cancer therapies. Watch combinations with Agenus antibodies and adjuvants, which MiNK can access under license while developing its own pipeline independently.
GSK plc earningsGSK
GSK’s report will show how Shingrix and Arexvy are selling, offering a read on whether these QS-21 vaccines continue to support an important revenue line for Agenus.
Watch sales of Shingrix and Arexvy, then compare them with the QS-21 royalty revenue Agenus reports afterward. Steady or rising vaccine sales would support this revenue line in Agenus’s accounts; weaker sales would put it under pressure. But the royalties are noncash revenue paid by GSK directly to HCR, so stronger sales do not mean more cash reaches Agenus.
Exelixis Inc earningsEXEL
Exelixis’s report will show how its zanzalintinib-plus-atezolizumab regimen is progressing, in a direct contest for some of the refractory colorectal cancer patients Agenus seeks to treat.
Look for updates on STELLAR-303 and the regulatory path for the U.S. application; the trial targets refractory colorectal cancer that is non-MSI-H/dMMR. Continued trial or application progress would bring another treatment option closer to the same patients and sharpen competition for Agenus; a delay or weak result would ease that pressure for now, but would not prove BOT/BAL works.
Agenus Inc. earningsThis company
Agenus’s report will show whether its BOT/BAL access programs are bringing in more revenue while the company retains resources to fund development.
Compare revenue from BOT/BAL access programs with operating cash use, available cash and debt needs; total revenue is not the same as cash, because GSK’s QS-21 royalties are recorded as revenue but paid directly to HCR. More access-program revenue, contained cash use and enough liquidity for debt would show a broader revenue base and manageable funding pressure; little access revenue alongside heavy cash use would leave Agenus needing outside financing to fund development.
MiNK Therapeutics, Inc. earningsINKT
MiNK’s report will show how its cell-therapy pipeline and licensed combinations are progressing, giving Agenus readers a view of a company in which Agenus holds a material stake.
Read MiNK’s trial updates alongside its funding position, including whether it advances combinations using Agenus antibodies or adjuvants. Clinical progress with resources to continue development would give more business support to Agenus’s roughly 46% stake and licensed assets; funding strain or stalled programs would weaken that case, but MiNK’s report alone cannot establish how Agenus’s recorded investment value changes.
